May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Long Term Outcomes of Intraoperative 5-Fluorouracil versus Intraoperative Mitomycin C in Primary Trabeculectomy Surgery
Author Affiliations & Notes
  • J. A. Hall
    Ophthalmology, Indiana University School of Medicine, Indianapolis, Indiana
  • D. WuDunn
    Ophthalmology, Indiana University School of Medicine, Indianapolis, Indiana
  • L. B. Cantor
    Ophthalmology, Indiana University School of Medicine, Indianapolis, Indiana
  • A. M. Palanca-Capistrano
    Ophthalmology, Indiana University School of Medicine, Indianapolis, Indiana
  • J. Hoop
    Ophthalmology, Indiana University School of Medicine, Indianapolis, Indiana
  • L. Morgan
    Ophthalmology, Indiana University School of Medicine, Indianapolis, Indiana
  • Footnotes
    Commercial Relationships  J.A. Hall, None; D. WuDunn, None; L.B. Cantor, None; A.M. Palanca-Capistrano, None; J. Hoop, None; L. Morgan, None.
  • Footnotes
    Support  Research to Prevent Blindness, Inc., New York, NY.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 4539. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J. A. Hall, D. WuDunn, L. B. Cantor, A. M. Palanca-Capistrano, J. Hoop, L. Morgan; Long Term Outcomes of Intraoperative 5-Fluorouracil versus Intraoperative Mitomycin C in Primary Trabeculectomy Surgery. Invest. Ophthalmol. Vis. Sci. 2008;49(13):4539.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose:
 

Long-term follow-up of those subjects previously enrolled in a prospective double masked clinical trial, involving the evaluation of a single intraoperative application of mitomycin C (MMC) versus 5-fluorouracil (5-FU) during primary trabeculectomy.

 
Methods:
 

92 eyes were analyzed, which included those followed beyond 12 months postoperatively and those which failed prior to 1 year. During the initial phase of the study, eyes were prospectively randomized in a double-masked fashion into one of two treatment groups at a single institution. In group one, primary trabeculectomies were performed with topical 5-FU (50 mg/ml for 5 minutes), and in group 2 with topical MMC (0.2 mg/ml for 2 minutes). The primary outcome measure was Kaplan-Meier success for IOP control (IOP >20% reduction from preoperative value and <21 mmHg). Secondary outcome measures included IOP, best-corrected visual acuity, number of glaucoma medications, postoperative interventions, and complications.

 
Results:
 

115 eyes of 103 patients were enrolled in the original study. Of these, 92 eyes entered the long-term follow-up, 46 of which were included in each study group. At 60 months post-trabeculectomy, 27 eyes from the 5-FU group (60%) and 23 eyes which received MMC (53.5%) were a success. The overall difference in Kaplan-Meier success between the two groups was not statistically significant (P=0.42, log rank test). Complication comparisons can be found in table 1.

 
Conclusions:
 

Our study suggests that intraoperative topical 5-FU continued to demonstrate at least equal efficacy and safety when compared with intraoperative topical MMC in primary trabeculectomy, at up to 60 months.  

 
Keywords: intraocular pressure • clinical (human) or epidemiologic studies: outcomes/complications • trabecular meshwork 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×